Abstract
Intrathecal drug delivery may be performed for malignant pain, nonmalignant pain, and spasticity. In all cases, patients must have persistent, debilitating pain or spasticity not responsive to more conservative treatments. They must also first undergo a trial of neuraxially administered medication showing at least a 50 % improvement in pain or functional status. These patients must be very carefully selected; contraindications include but are not limited to concurrent active infection, severe psychological comorbidities (e.g., substance abuse), and an inability to comply with medication refill schedule.
CPT
Implantation, revision, or replacement of catheter 62350
Implantation, revision, or replacement of pump 62360
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Additional Reading
Deer TR, Smith HS, Burton AW, et al. Comprehensive consensus guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain. Pain Physician. 2011;214:E283–312.
Deer TR, Smith HS, Cousins M, et al. Consensus guidelines for the selection and implantation of patients with noncancer pain for intrathecal drug delivery. Pain Physician. 2010;13:E175–213.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Abrecht, C.R., Narang, S. (2017). Intrathecal Drug Delivery. In: Yong, R., Nguyen, M., Nelson, E., Urman, R. (eds) Pain Medicine. Springer, Cham. https://doi.org/10.1007/978-3-319-43133-8_102
Download citation
DOI: https://doi.org/10.1007/978-3-319-43133-8_102
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-43131-4
Online ISBN: 978-3-319-43133-8
eBook Packages: MedicineMedicine (R0)